Patents by Inventor Artur J. Ulmer

Artur J. Ulmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160184404
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one Toll-like receptor (TLR)-activating amphiphilic lipid and at least one hemoglobin-derived peptide and optionally a pharmaceutically acceptable carrier. The present invention also relates to the pharmaceutical composition according to the invention for use in preventing and/or treating tumours, preventing and/or treating infections, preventing and/or treating allergies, preventing and/or treating age-related immune imbalances, stimulating the innate and adaptive immune system and/or alleviating the adverse side effects of irradiation. Moreover, the present invention also relates to a hemoglobin-derived peptide as well as its use in treating a bacterial infection.
    Type: Application
    Filed: April 11, 2014
    Publication date: June 30, 2016
    Inventors: Adrian HEINI, Ernst Theodor RIETSCHEL, Christian ALEXANDER, Klaus BRANDENBURG, Artur J. ULMER, Jean-Pierre MACH, Reginald M. GORCZYNSKI, Didier HEUMANN
  • Patent number: 7968103
    Abstract: The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the ?-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: June 28, 2011
    Inventors: Otto Westphal, Josette Westphal, legal representative, Alexander Westphal, legal representative, Thierry Walli, Reginald Gorczynski, Silke Muller, Jean-Pierre Mach, Alfred Hartman, Wolfgang Bessler, Petra Hofmann, Ulrich Zahringer, Christian Alexander, Ulrich vor dem Esche, Artur J. Ulmer, Antonio Verdini
  • Publication number: 20080075742
    Abstract: The present invention relates to a pharmaceutical composition representing a novel immunomodulating principle comprising bacterial endotoxin, fetal hemoglobin or more particularly a heme-free derivative or the ?-chain thereof, and optionally, components which are present in the fetal liver in addition to HbF. The composition is delivered to humans in a pharmaceutically acceptable carrier and/or diluent. In accordance with the present invention it was surprisingly found that endotoxin and fetal hemoglobin partial structures display a pronounced synergistic biomedical activity. The biomedical effect of fetal hemoglobin and its partial structures is surprisingly not based on a classical hemoglobin function as an oxygen transporter but related to a modulation of endotoxin-mediated bioactivity. This biomedical activity is surprisingly also observed after oral application of the composition.
    Type: Application
    Filed: February 18, 2004
    Publication date: March 27, 2008
    Inventors: Otto Westphal, Josette Mottier Westphal, Alexander Westphal, Thierry Walli, Reginald Gorczynski, Silke Muller, Jean-Pierre Mach, Alfred Hartman, Wolfgang Bessler, Petra Hofmann, Ulrich Zahringer, Christian Alexander, Ulrich vor dem Esche, Artur J. Ulmer, Antonio Verdini